NEW YORK (GenomeWeb) — OncoSec Medical, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it is working with the University of California, Los Angeles and PerkinElmer to develop molecular biomarkers to measure patients' immune responses to cancer.

OncoSeq said that the effort will use PerkinElmer’s imaging-based staining methods to quantitatively evaluate CD8+ T cell density, with the goal of developing markers that can distinguish responders from non-responders to anti-PD-1 monotherapies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.